Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации10773UnclassifiedMonitoring of adherence to psychopharmacotherapy during the first episode of psychosis at inpatient and outpatient stagesChinarevVitaly Aleksandrovich<p>Assistant, Head of Department, psychiatrist</p>v.chinarev@okspnb.ruhttps://orcid.org/0000-0003-3471-5293MalininaElena Viktorovnamalinina.e@rambler.ruhttps://orcid.org/0000-0002-5811-4428Regional Clinical Specialized Neuropsychiatric Hospital No. 1South Ural State Medical University of the Ministry of Health of the Russian Federation041120251421451473003202530072025Copyright © 2025, Chinarev V.A., Malinina E.V.2025<p>Adherence to psychopharmacotherapy is a key factor in determining the effectiveness of treatment for patients with their first episode of psychosis. Low levels of compliance are associated with an increased risk of relapse, hospitalization, and chronicity of the disorder. This emphasizes the need for systematic monitoring throughout all stages of care. In the context of psychotic disorders, it is becoming more relevant to take a differentiated approach to assessing and maintaining adherence in both inpatient and outpatient settings, considering the specific clinical, psychosocial, and organizational factors involved. The first episode of psychosis, such as the onset of schizophrenia, bipolar disorder, or other psychotic conditions, presents a unique opportunity for intervention due to the high plasticity of neurobiological and psychological processes. This creates a "therapeutic window" in which remission can be achieved.. However, up to 50% of patients discontinue taking antipsychotic medications within the first year following diagnosis, due to various reasons, including a lack of understanding about the disease (anosognosia) and the occurrence of adverse events. Therefore, adherence monitoring should be incorporated into clinical practice as an ongoing process tailored to the different stages of treatment.</p>first psychotic episodeschizophrenia debutschizophreniacommitmentpsychopharmacotherapyпервый психотический эпизоддебют шизофрениишизофренияприверженностьпсихофармакотерапия1.Чинарев, В. А. Нелеченный психоз в анамнезе: влияние на прогноз параноидной шизофрении. Клинический случай / В. А. Чинарев, Е. В. Малинина, М. Д. Обухова // Психиатрия. – 2024. – Т. 22, № 6. – С. 72-81. – DOI 10.30629/2618-6667-2024-22-6-72-81. – EDN FBFYMG.2.Петрова НН, Цыренова КА. Клинико-терапевтические факторы, влияющие на социальную адаптацию больных шизофренией. Психиатрия. 2021;19(4):26-33. DOI: 10.30629/2618-6667-202119-4-26-333.Friis S, Melle I, Johannessen JO, Røssberg JI, Barder HE, Evensen JH, Haahr U, Ten Velden Hegelstad W, Joa I, Langeveld J, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum PW, McGlashan TH. Early Predictors of Ten-Year Course in First-Episode Psychosis. Psychiatr Serv. 2016 Apr 1;67(4):438-443. 10.1176/appi.ps 2014005584.Чинарев, В. А. Первый психотический эпизод: клинико-диагностические аспекты и терапевтические подходы / В. А. Чинарев, Е. В. Малинина // Доктор.Ру. – 2024. – Т. 23, № 7. – С. 102-112. – DOI 10.31550/1727-2378-2024-23-7-102-112. – EDN ALCFQM.5.Чинарев, В. А. Первый психотический эпизод: клинико-диагностические аспекты и терапевтические подходы / В. А. Чинарев, Е. В. Малинина // Доктор.Ру. – 2024. – Т. 23, № 7. – С. 102-112. – DOI 10.31550/1727-2378-2024-23-7-102-112. – EDN ALCFQM.